TrialJCO precision oncology2026

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With

Maria Vieito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.